ANI Pharma (ANIP) Reports Q4 EPS of 84c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
ANI Pharmaceuticals Reports Full Year 2016 Results and Fourth Quarter Results and Provides 2017 Guidance
March 2, 2017 8:30 AM ESTBAUDETTE, Minn., March 2, 2017 /PRNewswire/ --
For the full year ended December 31, 2016:
Record net revenues of $128.6 million, an increase of 69% versus the prior year GAAP net income of $3.9 million, including $6.7 million non-cash impairment charge for a non-core asset Diluted GAAP earnings per share of $0.34, including impact of non-cash impairment charge of $0.36, net of tax Adjusted non-GAAP EBITDA of $61.1 million Adjusted non-GAAP net income per diluted share of $3.78 (previous methodology)For the fourth quarter 2016:
Net... More